The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Coach Amorim vows to stay with Sporting Lisbon after winning another Portuguese league
Rebel Wilson thanks people for 'acknowledging my experiences with Sacha Baron Cohen'
Anaheim Ducks goaltending coach Sudarshan Maharaj declared cancer
2024 NFL draft: Browns' draft picks from Michigan
A closer look at China's economic steadiness, vitality and potential
Eddie Murphy's The Pickup set crash saw two stunt vehicles collide and roll off the road
Beyonce puts on a cheeky display in bottom
Police release new image of 74
Emerging trends for upcoming May Day holiday
Channel 4 is set to make major change to Gogglebox 11 years after the show began